Ozempic Is Not the Finish Line: The Truth About GLP-1 Weight Loss, Muscle Loss, and Long-Term Results
- Dragos Mutascu
- May 12
- 18 min read
Ozempic and other GLP-1 medications can help people lose significant weight by reducing appetite, improving blood sugar regulation, slowing gastric emptying, and influencing hunger signals in the brain. However, weight loss is not automatically the same as healthy fat loss. Without enough protein, resistance training, and long-term lifestyle structure, some of the weight lost may include lean mass, and many people regain weight after stopping medication. GLP-1s can be a powerful tool, but they are not the finish line; they work best when paired with a complete nutrition, training, and behavior strategy.
Introduction: The Injection Can Start the Journey, But It Cannot Finish It
Ozempic has become one of the most talked-about medications in modern health, fitness, and weight loss culture. For some people, it has been life-changing. For others, it has created confusion, fear, unrealistic expectations, or disappointment. The conversation has become loud, but not always intelligent.
On one side, some people treat GLP-1 medications as miracle drugs that make discipline, nutrition, training, and lifestyle irrelevant. On the other side, some people dismiss them entirely, as if medical support for obesity is somehow cheating. Both views miss the real physiology.
Ozempic, Wegovy, and other GLP-1-based medications are not magic. They are also not meaningless. They interact with some of the most powerful systems in the human body: appetite regulation, glucose control, gastric emptying, insulin secretion, satiety signalling, and the brain’s relationship with food. Semaglutide, the active ingredient in Ozempic and Wegovy, has been shown in major clinical trials to produce significant weight loss in adults with overweight or obesity, especially when paired with lifestyle intervention. In the STEP 1 trial, once-weekly semaglutide 2.4 mg led to substantially greater body weight reduction than placebo over 68 weeks.
But here is where the story becomes more sophisticated.
The scale does not tell you what kind of weight you are losing. A lower body weight can mean less fat mass, less water, less gut content, less glycogen, and sometimes less lean tissue. The body does not simply burn fat in a perfectly clean, elegant manner because appetite has been reduced. It adapts. It economizes. It protects survival. It can reduce energy expenditure, increase hunger after discontinuation, and regain weight when the external appetite signal is removed. In the STEP 1 extension, participants regained a substantial portion of lost weight after stopping semaglutide, showing that the biology of obesity does not simply disappear when the prescription ends.
This is why Ozempic is not the finish line. It may help open the gate, but the road still requires structure, muscle, nutrition, training, sleep, metabolic literacy, and long-term behavioral architecture. In other words, the medication may quiet the appetite orchestra, but someone still has to conduct the symphony.
What Are GLP-1 Medications and How Do They Work?
GLP-1 stands for glucagon-like peptide-1, a hormone naturally produced in the gut after eating. It helps the body manage blood sugar and appetite. When food enters the digestive system, GLP-1 is released and begins communicating with multiple organs, including the pancreas, stomach, liver, and brain.
In simple language, GLP-1 helps the body say: “Food has arrived. Slow down. Release insulin appropriately. Reduce unnecessary hunger. Let’s manage this meal intelligently.”
GLP-1 receptor agonists are medications that mimic or enhance this natural hormone signal. They bind to GLP-1 receptors and produce effects that can include increased glucose-dependent insulin secretion, reduced glucagon secretion, delayed gastric emptying, and increased satiety. This means they can help people feel full sooner, stay full longer, and experience less intense food noise or compulsive hunger. Reviews of GLP-1 physiology describe these medications as acting through both peripheral metabolic pathways and central nervous system mechanisms that influence appetite and energy regulation.
This is one of the reasons GLP-1s can feel so dramatic for people who have struggled with constant hunger. For someone whose brain has been living in a never-ending snack opera, GLP-1 therapy can lower the volume. The fridge stops whispering poetry at midnight. The pantry becomes furniture again.
But this appetite reduction comes with a catch.
When appetite drops, total food intake often drops. That can be beneficial if someone has been chronically overeating. However, if intake drops too aggressively or without structure, the person may unintentionally under-consume protein, fibre, micronutrients, and total energy needed to support training, recovery, bone health, and lean mass preservation. A lower appetite is helpful only when the remaining diet is built with precision.
This is why nutrition coaching becomes more important, not less important, during GLP-1 use.
Ozempic, Wegovy, Semaglutide, and the Difference Between Diabetes and Weight-Loss Dosing
Ozempic and Wegovy are both brand names associated with semaglutide, but they are used differently. Ozempic is commonly prescribed for type 2 diabetes management, while Wegovy is approved specifically for chronic weight management in appropriate patients. The medication, dose, indication, and monitoring should always be determined by a licensed medical professional.
The distinction matters because many people use “Ozempic” as a cultural shorthand for all GLP-1 weight-loss medications. In reality, the category includes multiple drugs and drug combinations, including semaglutide and tirzepatide. Tirzepatide acts on both GIP and GLP-1 pathways and has shown very large weight-loss effects in obesity trials. In the SURMOUNT-1 trial, tirzepatide produced substantial body weight reductions in adults with obesity or overweight without diabetes.
The purpose of this article is not to tell anyone which medication to use. That decision belongs between the individual and their healthcare provider. The purpose here is to explain a deeper truth: regardless of the medication used, the body still requires a long-term strategy.
Medication may reduce appetite. It does not automatically build muscle.
Medication may improve glucose control. It does not automatically teach meal timing.
Medication may reduce weight. It does not automatically create metabolic resilience.
Medication may help someone start. It does not automatically help them finish.
That final part is where structured coaching becomes essential.
Weight Loss Is Not the Same as Fat Loss
Most people say they want to lose weight. But physiologically, that is not quite accurate.
What most people truly want is to lose excess fat while keeping or building muscle, preserving bone health, improving blood markers, increasing energy, reducing pain, improving confidence, and looking healthier. That is not simply “weight loss.” That is body recomposition, metabolic improvement, and lifestyle transformation.
The scale is a blunt instrument. Useful, yes, but blunt. It cannot tell you whether the body is becoming more athletic, more resilient, more insulin-sensitive, or merely smaller.
In the STEP 1 body composition substudy, semaglutide led to reductions in both fat mass and lean body mass, with greater reductions in fat mass than lean mass. Total fat mass and visceral fat decreased, which is a positive metabolic outcome, but lean body mass also decreased in absolute terms.
This is not unique to Ozempic. Lean mass loss can happen with almost any significant weight-loss method, including dieting, bariatric surgery, and aggressive calorie restriction. When the body is in an energy deficit, it uses stored energy. Ideally, most of that energy comes from fat tissue. But without resistance training and sufficient protein, the body has less reason to protect skeletal muscle.
Muscle is metabolically expensive tissue. It requires energy to maintain. If the body senses prolonged calorie restriction and no mechanical demand from strength training, it may decide that carrying extra muscle is unnecessary. The body is not trying to ruin your physique. It is trying to survive efficiently. Unfortunately, survival efficiency and looking powerful in a fitted shirt are not always aligned.
This is one of the key issues with GLP-1 weight loss. People may eat less without realizing that they are also training less, moving less, and consuming less protein. The result may be impressive scale loss but weaker long-term body composition.
At Physion Dynamics, this is why we never look at the scale alone. A successful transformation should ask: What happened to strength? What happened to waist circumference? What happened to energy? What happened to protein intake? What happened to sleep? What happened to performance? What happened to confidence? What happened to the person’s ability to maintain this body after the medication is reduced or stopped?
That is the real assessment.
For deeper context, this article connects closely with our Physion Dynamics blog on The Truth About Fat Loss: What No One’s Telling You, where we explain why fat loss is not simply about eating less, but about creating the right biological environment for sustainable change.
The Muscle Loss Question: Should People Be Concerned?
The concern around GLP-1 medications and muscle loss has become one of the biggest topics in obesity medicine and fitness. The truth is nuanced.
GLP-1 medications do not appear to “attack muscle” directly. They reduce appetite and body weight. When body weight drops significantly, some lean mass loss is expected. The important question is whether the lean mass loss is excessive, harmful, preventable, or functionally meaningful.
Recent scientific discussion has become more balanced. A 2024 Circulation primer addressed whether muscle-related changes associated with weight-loss treatments such as GLP-1 receptor agonists are maladaptive, emphasizing that the interpretation depends on the amount of weight lost, the proportion of fat versus lean tissue lost, and functional outcomes such as strength and mobility.
This is important because losing some absolute lean mass during major weight loss is not always automatically pathological. A person in a larger body often carries more total lean mass partly because moving a heavier body requires more tissue and support. When body mass decreases, some reduction in lean mass can occur as part of the new body size. But that does not mean we should shrug and ignore it.
There is a difference between expected lean mass reduction and preventable muscle wasting.
The goal is not to avoid any change in lean mass at all costs. The goal is to preserve as much high-quality skeletal muscle and strength as possible while reducing excess fat. That requires a deliberate strategy.
Protein becomes non-negotiable. Resistance training becomes non-negotiable. Recovery becomes non-negotiable. Progressive overload becomes non-negotiable. A person using GLP-1 therapy should not be wandering through weight loss blindly, hoping their body magically chooses fat and spares muscle out of politeness. Biology is powerful, but it is not sentimental.
This is where a proper coaching system matters. Training tells the body, “This muscle is needed.” Protein gives the body the raw material to repair and maintain that muscle. Sleep and recovery regulate the hormones and nervous system environment that allow adaptation. Nutrition timing helps manage energy and training quality. Together, these are the signals that protect the body from becoming merely smaller instead of stronger, healthier, and more capable.
This connects directly with our Physion Dynamics article on SHBG & Testosterone: The Hidden Factor Sabotaging Your Results, because hormones, energy availability, lean mass, and long-term physique outcomes are deeply connected.
Protein Intake on GLP-1s: Why Eating Less Can Create a New Problem
One of the most common effects of GLP-1 therapy is reduced appetite. For someone struggling with overeating, this can feel liberating. But appetite suppression does not automatically create a high-quality diet. It simply creates less desire to eat.
That means a person may eat fewer calories, but also fewer nutrients.
A small breakfast, half a salad, a few bites of dinner, and a protein bar may produce weight loss. But it may not provide enough protein, iron, calcium, vitamin D, omega-3 fats, magnesium, fibre, or total micronutrients to support long-term health. Nutritional priorities during GLP-1 therapy have become an important topic because reduced intake can increase the risk of inadequate nutrient consumption, gastrointestinal discomfort, dehydration, constipation, and poor diet quality if not managed carefully. A 2025 review in The American Journal of Clinical Nutrition noted that GLP-1 therapies can produce major weight loss but also create challenges related to gastrointestinal side effects, nutritional deficiencies, muscle and bone loss, long-term adherence, and weight regain after discontinuation.
This is why the Physion approach would never be: “You are less hungry now, so just eat less.”
That is too primitive. That is cave-wall nutrition.
A better approach is: “Your appetite has changed, so now your diet must become more precise.”
Protein should usually be prioritized early in the meal because many GLP-1 users become full quickly. Lean meats, eggs, Greek yogurt, cottage cheese, high-quality protein powders, legumes, tofu, or other protein-rich foods may be necessary depending on preferences and tolerance. Fiber should be introduced intelligently, because it helps gut health and satiety but may worsen bloating if increased too aggressively. Hydration and electrolytes matter because lower food intake can also mean lower fluid and sodium intake. Calcium and vitamin D matter because rapid weight loss and inadequate intake may affect bone health over time.
This is where Physion Performance Meals can become a powerful support system. A GLP-1 user may not need large chaotic meals, but they do need structured, protein-forward, nutrient-dense meals that make every bite count. When appetite is lower, food quality becomes louder.
In luxury transformation coaching, we are not simply asking, “How little can you eat?”
We are asking, “How intelligently can we nourish the body while fat loss occurs?”
The Brain, Food Noise, and Why GLP-1s Feel So Powerful
One of the most fascinating parts of GLP-1 therapy is its effect on what many people call “food noise.” This term describes persistent thoughts about food, cravings, snacking, emotional eating, or the feeling that appetite is always knocking on the skull like a tiny salesman with no shoes.
GLP-1 signalling does not only work in the gut. It also interacts with the brain. GLP-1 receptors are involved in appetite regulation, satiety, reward, and food-related decision making. Modern research continues to explore how GLP-1 pathways influence eating control through gut-brain communication and neural circuits related to hunger, gastric distension, reward, and satiety.
For many people, this is the most emotionally powerful effect. They do not just feel physically full. They feel mentally quieter. Food becomes less intrusive. Cravings may become less aggressive. Eating may become less impulsive.
That can create a window of opportunity.
But a window is not a house.
If someone uses that quieter period to build better routines, improve protein intake, learn hunger and fullness cues, increase steps, strength train, improve sleep, manage stress, and reshape their environment, the medication-assisted period can become a bridge to long-term change. But if they rely entirely on appetite suppression without building skills, the removal of that appetite suppression can reveal the same old patterns underneath.
This is one of the most important messages of this entire article.
GLP-1s can reduce the pressure. They do not automatically teach the person how to live differently.
That education must be built.
This connects with our Physion Dynamics blog What Makes a Good Coach? Here’s What I Promise My Clients, because coaching is not just giving macros. It is helping someone build a life where the result can survive.
What Happens After Stopping Ozempic or GLP-1 Medication?
This is the question many people avoid because the answer is uncomfortable: weight regain is common after stopping GLP-1 medication.
In the STEP 1 trial extension, participants who stopped semaglutide regained a large portion of the weight they had lost. The authors concluded that ongoing treatment may be required to maintain improvements in weight and cardiometabolic health for many people with obesity.
This does not mean GLP-1 therapy is useless. That would be the wrong conclusion. Many chronic conditions require ongoing treatment. Blood pressure medication works while being taken. Cholesterol medication works while being taken. Obesity is increasingly understood as a chronic, relapsing, biologically defended condition, not simply a failure of willpower.
But it does mean we need honesty.
If a person loses weight because appetite is pharmacologically reduced, and then the medication is removed, appetite may increase again. Energy intake may rise. Old habits may return. Metabolic adaptations from weight loss may make maintenance harder. The body may defend its previous weight through hunger signals, reduced energy expenditure, and increased food reward.
This is why the exit strategy matters.
A GLP-1 plan should not only ask, “How do we lose weight?”
It should ask:
“How do we protect muscle while losing weight?”
“How do we build a maintenance diet?”
“How do we train through the process?”
“How do we prevent rebound eating?”
“How do we monitor strength, waist, sleep, digestion, and energy?”
“How do we transition if the medication dose changes?”
“How do we maintain identity after the scale changes?”
That last question is not fluffy. It is crucial. Many people lose weight physically before they change psychologically. If the person still sees themselves as someone who is temporarily dieting, temporarily taking medication, temporarily being “good,” then long-term maintenance is fragile. The goal is to become someone who lives with structure naturally, not someone who survives on temporary restriction.
This is where the Physion Dynamics model becomes valuable. We do not just chase weight loss. We build the architecture around the result.
GLP-1s and Cardiometabolic Health: The Benefits Are Real
A balanced article must also be clear about something important: GLP-1 medications can have real health benefits beyond appearance.
Semaglutide has been studied not only for weight loss but also for cardiometabolic outcomes. In the SELECT trial, semaglutide reduced major adverse cardiovascular events in adults with overweight or obesity and established cardiovascular disease but without diabetes.
This matters because obesity is not merely a cosmetic issue. It is associated with increased risk of type 2 diabetes, cardiovascular disease, sleep apnea, joint stress, fatty liver disease, systemic inflammation, and reduced quality of life. For some individuals, GLP-1 therapy may provide meaningful medical support when lifestyle intervention alone has not been enough.
The premium, intelligent stance is not anti-medication. It is anti-fragile-results.
A medication can be part of a powerful plan. But it should not be mistaken for the entire plan.
If GLP-1 therapy helps someone reduce appetite, improve blood sugar, lose dangerous visceral fat, lower cardiometabolic risk, and regain control, that is significant. But the next question is: what kind of body and lifestyle are being built underneath that medical assistance?
At Physion Dynamics, the answer should be: a stronger one.
Why Strength Training Is the Missing Piece in GLP-1 Weight Loss
If GLP-1 therapy reduces appetite and creates weight loss, resistance training helps tell the body what to keep.
Strength training provides a mechanical signal to skeletal muscle. It tells the body that muscle tissue is not decorative. It is required. It is being used. It must be maintained and upgraded.
This becomes especially important during weight loss, because calorie deficits reduce the body’s resources. Without training, the body has fewer reasons to preserve muscle. With training, adequate protein, and intelligent programming, the body receives a very different message: lose fat, but keep the engine.
Exercise and GLP-1 therapy are increasingly discussed together because the combination may support better long-term outcomes than medication alone. A 2025 review argued that GLP-1 receptor agonists should not replace lifestyle priorities, and that exercise remains essential for preserving functional capacity, cardiometabolic health, and long-term results.
The training does not need to be extreme. In fact, for many GLP-1 users, extreme training may be inappropriate at first if calories are low, digestion is sensitive, or energy is reduced. The better approach is progressive, strategic, and individualized.
A strong program may include full-body resistance training, mobility work, walking, cardiovascular conditioning, core stability, posture correction, and gradual progression based on recovery. The goal is not to punish the body into submission. The goal is to give it a reason to become capable.
This is also why our Physion Dynamics blog on How to Prevent and Manage Joint Aches in the Gym Before They Become Injuries belongs in the same topic cluster. As people lose weight and begin training, they need safe progression, joint-friendly programming, and intelligent exercise selection.
The medication may make weight loss easier. Strength training makes the result worth keeping.
The Long-Term Physion Dynamics Approach: Medication, Muscle, Meals, and Maintenance
The future of weight loss will not be one-dimensional. It will not be “just diet.” It will not be “just medication.” It will not be “just workouts.” The highest-level transformations will come from integrated systems.
For a client using GLP-1 therapy, a Physion-style plan would focus on several major outcomes: preserving lean tissue, building strength, maintaining adequate protein, improving digestion, supporting hydration, monitoring energy, adjusting meal size, improving sleep, tracking waist and performance, and preparing for long-term maintenance.
This is the difference between weight loss and transformation.
Weight loss asks, “How fast can the scale move?”
Transformation asks, “What is the body becoming?”
A luxury coaching model should also consider the person’s lifestyle. Busy professionals, executives, parents, athletes, and older adults all require different strategies. A CEO on GLP-1 therapy may need travel meal planning, restaurant guidance, hotel gym programming, wearable tracking, and high-protein meal delivery support. A senior may need muscle preservation, bone health support, fall prevention, and physician communication. A younger adult may need education around body image, long-term habits, and strength development.
This is why Physion Dynamics fits naturally into the GLP-1 conversation. The medication may reduce appetite, but Physion builds the system around the human.
Frequently Asked Questions
1. Does Ozempic make you lose muscle?
Ozempic does not appear to directly “burn muscle,” but significant weight loss from any method can include some loss of lean mass. In semaglutide body composition research, participants lost more fat mass than lean mass, but lean body mass still decreased in absolute terms. The best way to reduce unnecessary muscle loss is to combine GLP-1 therapy with adequate protein, resistance training, sleep, and a properly structured nutrition plan.
2. Can you build muscle while taking Ozempic or a GLP-1 medication?
It may be possible to build or preserve muscle while using GLP-1 medication, but it depends on the person’s training experience, protein intake, calorie intake, recovery, age, and program design. Beginners may gain strength and muscle more easily, while advanced trainees may need a more precise plan because appetite suppression can make eating enough protein and calories difficult. The key is to treat training and nutrition as part of the medical weight-loss strategy, not as optional decoration.
3. What should you eat while taking a GLP-1 medication?
A GLP-1 nutrition plan should prioritize protein, fibre, hydration, micronutrients, and easy-to-digest meals. Since appetite may be lower, every meal needs to be more intentional. Protein-rich foods, colourful vegetables, fruits, healthy fats, and slow-digesting carbohydrates can help preserve muscle, support digestion, and maintain energy. Some people may need smaller, more frequent meals to avoid nausea or discomfort.
4. Will weight come back after stopping Ozempic?
Weight regain is common after stopping GLP-1 medication. In the STEP 1 extension study, participants regained a substantial portion of the weight they had lost after discontinuing semaglutide. This does not mean the medication failed. It means long-term maintenance requires a plan. Strength training, protein intake, calorie awareness, habit formation, stress management, and ongoing coaching can help reduce the risk of rebound.
5. Is Ozempic better than diet and exercise?
Ozempic and GLP-1 medications can produce powerful weight-loss results, especially for individuals with obesity or metabolic disease, but they should not be viewed as a replacement for nutrition and exercise. Medication can reduce appetite and improve metabolic markers, while exercise and nutrition help preserve muscle, support heart health, improve strength, protect bone health, and build long-term habits. The strongest approach is often not medication versus lifestyle; it is medication supported by lifestyle.
6. How much protein should someone eat while taking Ozempic?
Protein needs vary based on body weight, goal weight, activity level, medical history, kidney health, and training intensity. Many active individuals pursuing fat loss benefit from a higher-protein approach, but anyone with kidney disease or medical complications should follow physician or dietitian guidance. The main principle is simple: when appetite is reduced, protein should not accidentally disappear from the diet. It should become the anchor.
7. Is Ozempic safe for weight loss?
Safety depends on the individual, the dose, the indication, medical history, side effects, and medical supervision. GLP-1 medications can cause gastrointestinal side effects and may not be appropriate for everyone. Health Canada has warned consumers to avoid fake or unauthorized GLP-1 products and emphasizes that these medications should be used under professional medical supervision. Anyone considering GLP-1 therapy should speak with a licensed healthcare provider.
Final Thoughts: The Goal Is Not Just to Be Smaller
Ozempic and GLP-1 medications have changed the weight-loss conversation forever. They have shown that appetite, obesity, and metabolic disease are not simply matters of willpower. They have given many people a tool that can reduce hunger, improve health markers, and create meaningful weight loss.
But the deeper truth remains: becoming lighter is not the same as becoming healthier, stronger, or metabolically resilient.
The finish line is not the injection. The finish line is the body and lifestyle you can maintain when life becomes stressful, appetite changes, travel interrupts your schedule, motivation fades, and the novelty disappears. That requires more than appetite suppression. It requires muscle. It requires nutrition. It requires training. It requires structure. It requires education. It requires a plan designed around the person, not just the prescription.
At Physion Dynamics, we believe the future of transformation is not shame, extremes, or shortcuts. It is precision. It is science. It is coaching. It is building a body that does not just lose weight, but gains capacity.
Ozempic may help open the door.
But you still have to build the house.
Connected Physion Dynamics Topic Series
This article is part of the larger Physion Dynamics educational series:
The Physion Metabolic Transformation Series
This series explores the science of fat loss, hormones, muscle preservation, inflammation, nutrition, and long-term body recomposition.
The Truth About Fat Loss: What No One’s Telling You
Fat loss is not just about eating less
What Makes a Good Coach? Here’s What I Promise My Clients
Why coaching matters for long-term transformation
SHBG & Testosterone: The Hidden Factor Sabotaging Your Results
How hormones influence body composition
Coffee and Antioxidants: How Much Is Healthy?
Nutrition quality and metabolic health
How Much Calcium Do You Need for Strong Bones and How to Get It
Bone health during weight loss
How to Prevent and Manage Joint Aches in the Gym Before They Become Injuries
Safe strength training during transformation
Albumin and Testosterone: The Overlooked Connection
Protein status and hormonal health
References
Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
Wilding JPH, Batterham RL, Davies M, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes, Obesity and Metabolism. 2022.
Wilding JPH, Batterham RL, et al. Impact of Semaglutide on Body Composition in Adults With Overweight or Obesity. Journal of the Endocrine Society / STEP 1 body composition analysis.
Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. New England Journal of Medicine. 2023.
Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
Look M, et al. Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 trial. 2025.
Linge J, et al. Muscle Mass and Glucagon-Like Peptide-1 Receptor Agonists. Circulation. 2024.
Mozaffarian D, et al. Nutritional priorities to support GLP-1 therapy for obesity. The American Journal of Clinical Nutrition. 2025.
Codella R, et al. GLP-1 agonists and exercise: the future of lifestyle prioritization. 2025.
Liu QK, et al. Mechanisms of action and therapeutic applications of GLP-1 and related incretin therapies. Frontiers in Endocrinology. 2024.
Jones LA, et al. GLP-1 and the Neurobiology of Eating Control: Recent Advances. Endocrinology. 2025.
Health Canada. Thinking about buying GLP-1 drugs like Ozempic or Mounjaro? Beware of fake or unauthorized products. 2026.
Written by: Dumitru-Dragos Mutascu
Founder and Head Coach of Physion Dynamics
BA Kinesiology & Health Sciences, York University
Master’s in Kinesiology & Health Sciences, York University
Physiotherapy Student, McMaster University
ISSA Certified Personal Trainer Specialist
ISSA Nutrition & Wellness Specialist
At Physion Dynamics, we specialize in concierge-level fitness, nutrition, and lifestyle coaching designed to help clients lose fat, preserve muscle, improve health markers, and build long-term results through science-backed strategy, precision coaching, and individualized support.
Comments